Incidence, prevalence, mortality, and causes of death in Waldenstrom macroglobulinemia: a nationwide, population-based cohort study

被引:11
作者
Jeong, Seri [1 ]
Kong, Seom Gim [2 ]
Kim, Da Jung [3 ]
Lee, Sangjin [4 ]
Lee, Ho Sup [3 ]
机构
[1] Hallym Univ, Dept Lab Med, Coll Med, 1 Singil Ro, Seoul 07441, South Korea
[2] Kosin Univ, Dept Pediat, Coll Med, 262 Gamcheon Ro, Busan 49267, South Korea
[3] Kosin Univ, Dept Internal Med, Div Hematol Oncol, Coll Med, 262 Gamcheon Ro, Busan 49267, South Korea
[4] Pusan Natl Univ, Grad Sch, Dept Stat, 2,Busandaehak Ro 63 Beon Gil, Busan 46241, South Korea
基金
新加坡国家研究基金会;
关键词
Waldenstrom macroglobulinemia; Epidemiology; Incidence; Mortality; Survival; LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA; UNITED-STATES; MONOCLONAL GAMMOPATHY; INCIDENCE-PATTERNS; RISK; SURVIVAL; EPIDEMIOLOGY; SURVEILLANCE; RITUXIMAB; THERAPY;
D O I
10.1186/s12885-020-07120-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe epidemiological features of Waldenstrom macroglobulinemia (WM) have seldom been investigated at a national level, particularly in East Asia. The goal of our study is to present the incidence, prevalence, mortality, survival with competing risks, and causes of death of patients with WM.MethodsWe used a national population-based database, operated by the Health Insurance Review and Assessment Service of the Korean government. This data includes information on all WM patients diagnosed according to uniform criteria, between 2003 and 2016.ResultsThe total number of patients newly diagnosed with WM during the study period was 427, with a male-to-female ratio of 3.2:1. The incidence increased from 0.03 to 0.10 per 10(5) between 2003 and 2016, and the prevalence was 0.42 per 10(5) in 2016. A total of 217 patients with WM died during the study period (standardized mortality ratio=7.57), and the overall survival (OS) of WM patients was 47.5%. On multivariate analysis, older age was associated with worse OS (P< 0.0001). WM was the most common cause of death (n=102, 48.6%), followed by other malignant neoplasms (n=82, 39.0%).ConclusionsThe national incidence of WM in Korea, a racially homogeneous country in Asia, was lower than that in previous reports from other countries, reflecting ethnic disparities. However, the incidence increased, and mortality was the highest ever reported. The main cause of death was WM in itself. This study reflects the need for greater awareness of WM, particularly in Asian countries.
引用
收藏
页数:9
相关论文
共 35 条
[1]   Outcome Disparities among Ethntic Subgroups of Waldenstrom's Macroglobulinemia: A Population-Based Study [J].
Ailawadhi, Sikander ;
Kardosh, Adel ;
Yang, Dongyun ;
Cozen, Wendy ;
Patel, Gaurav ;
Alamgir, Mohammad A. ;
Chanan-Khan, Asher A. .
ONCOLOGY, 2014, 86 (5-6) :253-262
[2]   Rituximab therapy in Waldenstrom's macroglobulinemia:: Preliminary evidence of clinical activity [J].
Byrd, JC ;
White, CA ;
Link, B ;
Lucas, MS ;
Velasquez, WS ;
Rosenberg, J ;
Grillo-López, AJ .
ANNALS OF ONCOLOGY, 1999, 10 (12) :1525-1527
[3]   Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database [J].
Castillo, Jorge J. ;
Olszewski, Adam J. ;
Kanan, Sandra ;
Meid, Kirsten ;
Hunter, Zachary R. ;
Treon, Steven P. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (01) :81-89
[4]   Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database [J].
Castillo, Jorge J. ;
Olszewski, Adam J. ;
Cronin, Angel M. ;
Hunter, Zachary R. ;
Treon, Steven P. .
BLOOD, 2014, 123 (25) :3999-4000
[5]   Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004 [J].
Daniel Carreon, J. ;
Morton, Lindsay M. ;
Devesa, Susan S. ;
Clarke, Christina A. ;
Gomez, Scarlett L. ;
Glaser, Sally L. ;
Sakoda, Lori C. ;
Linet, Martha S. ;
Wang, Sophia S. .
CANCER CAUSES & CONTROL, 2008, 19 (10) :1171-1181
[6]  
Dimopoulos MA, 2005, HAEMATOLOGICA, V90, P1655
[7]   Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98) [J].
Gertz, MA ;
Rue, M ;
Blood, E ;
Kaminer, LS ;
Vesole, DH ;
Greipp, PR .
LEUKEMIA & LYMPHOMA, 2004, 45 (10) :2047-2055
[8]  
Groves FD, 1998, CANCER-AM CANCER SOC, V82, P1078
[9]   Excellent long-term survival of 170 patients with Waldenstrom's macroglobulinemia treated in private oncology practices and a university hospital [J].
Hensel, M. ;
Brust, J. ;
Ploeger, C. ;
Schuster, D. ;
Memmer, M. L. ;
Franz-Werner, J. ;
Feustel, H. -P. ;
Karcher, A. ;
Fuxius, S. ;
Mosthaf, F. A. ;
Rieger, M. ;
Ho, A. D. ;
Witzens-Harig, M. .
ANNALS OF HEMATOLOGY, 2012, 91 (12) :1923-1928
[10]  
HERRINTON LJ, 1993, BLOOD, V82, P3148